Abstract: The present disclosure relates to compounds of Formula (I): and to their pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are useful for inhibiting the maturation of cytokines of the IL-1 family by inhibiting inflammasomes and may be used in the treatment of disorders in which inflammasome activity is implicated, such as inflammatory, autoinflammatory and autoimmune diseases and cancers.
Type:
Grant
Filed:
October 17, 2022
Date of Patent:
June 18, 2024
Assignee:
NodThera Limited
Inventors:
David Harrison, Alan Paul Watt, Mark G. Bock
Abstract: The present disclosure relates to compounds of Formula (I): and to their pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are useful for inhibiting the maturation of cytokines of the IL-1 family by inhibiting inflammasomes and may be used in the treatment of disorders in which inflammasome activity is implicated, such as inflammatory, autoinflammatory and autoimmune diseases and cancers.
Type:
Grant
Filed:
December 18, 2018
Date of Patent:
December 6, 2022
Assignee:
NodThera Limited
Inventors:
David Harrison, Alan Paul Watt, Mark G. Bock
Abstract: The present disclosure relates to compounds of Formula (I): and to their pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein inhibit the maturation of cytokines of the IL-1 family by inhibiting inflammasomes and may be used in the treatment of disorders in which inflammasome activity is implicated, such as inter alia autoinflammatory and autoimmune diseases and cancers.
Type:
Grant
Filed:
March 12, 2018
Date of Patent:
May 31, 2022
Assignee:
NodThera Limited
Inventors:
David Harrison, Alan Paul Watt, Nicolas Boutard, Charles-Henry Fabritius, Michal Galezowski, Piotr Kowalczyk, Oleksandr Levenets, Jakub Woyciechowski
© 2024 Justia
